Strategic partners

“Bristol-Myers Squibb” LLC

Bristol Myers Squibb is the company of breakthroughs – the kind that transform patients` lives. Dedicated to our mission of discovering, developing and delivering life-saving innovations that help patients prevail over serious diseases, we`ll never give up our search for more hope, for more people, around the world.

We focus on innovations, as we believe in the power of science to address some of the most challenging diseases of our time. We have a history of scientific excellence, transforming patient outcomes in major diseases such as cancer, cardiovascular disease, HIV and HCV. We pioneered a class of medicines that harnesses the power of the immune system to treat cancer.

We aim to provide access to our medicines to all patients. Therefore, we take a thoughtful approach to pricing our medicines and support policies that help advance access. We are engaged in the global dialogue surrounding the affordability of our life-saving medicines.

We support programs, initiatives and organizations that help improve health, expand research opportunities, promote STEM education. We promote health equity globally and strive to increase access to life-saving medicines for those affected by serious diseases.

We are driven by the knowledge that our efforts can make the difference for patients.


AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in the main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and millions of patients use its innovative medicines worldwide.


BIOCAD is one of the largest international innovative biotech companies in Russia. It brought together world-class R&D centers, modern pharmaceutical and biotechnological production, and preclinical and clinical trials, compliant with international standards.

Present product portfolio includes 50 medical products, including 10 biological. More than 40 products are now in different development stages. Development of drugs for cancer therapy is one of the priorities of the company.

Trastuzumab, bevacizumab, and rituximab are the drugs, that are most frequently chosen by healthcare systems for therapies of different cancer types. When in 2014 BIOCAD started producing biosimilars, the availability of medical products for patients improved significantly.

The begging of the new era in cancer treatment started with immune-oncology. For immunotherapy of malignant tumors BIOCAD has a whole portfolio of products in different stages of development:

  • Inhibitors of immune response reference points, that aim different targets on programmed cell death pathway: anti PD-1 and anti PD-L1
  • Inhibitor of immune response reference points anti-CTLA-4 (cytoxic T-lymphocyte associated protein 4)
  • New drugs, operating on the level of anti OX40 receptors
  • Vaccines that potentiate the effect of drugs that inhibit immune response reference points
  • CAR-therapy and other latest scientific developments

There are more that 2200 people working in BIOCAD, including more that 650 scientists and researchers. Offices of the company are located in the USA, Brazil, China, India, Vietnam, Egypt, Finland, and other countries.

Johnson & Johnson LLC

ETHICON, part of the Johnson & Johnson, is more than 80 years of a world history of surgeon confidence and a continuous desire to improve surgical treatment improving the quality of life of patients.

The company's product portfolio includes:

  • Modern suture materials (more than 1000 thread codes for any area of surgical intervention);
  • High-tech hemostatic agents;
  • Electrosurgical instruments, including an ultrasonic scalpel «Harmonic» and bipolar instruments «EnSeal»;
  • Modern stapling and cutting devices for open and laparoscopic surgery;
  • Instruments for ligation of blood vessels;
  • High-tech solutions for hernia repair surgery;
  • Skin adhesives and drains;
  • Tools for endoscopic access.

Ethicon products and technologies are widely used in the fields of medicine such as oncology, thoracic surgery, heart surgery, neurosurgery, pediatric surgery, plastic surgery, coloproctology, urology, gynecology, and others.


We were founded in 1876 by Colonel Eli Lilly, a man committed to creating high-quality medicines that met real needs in an era of unreliable elixirs peddled by questionable characters. His charge to the generations of employees who have followed was this: “Take what you find here and make it better and better.”

More than 140 years later, we remain committed to his vision through every aspect of our business and the people we serve starting with those who take our medicines, and extending to health care professionals, employees and the communities in which we live. PP-LILLY-RU-0029 12.03.2019


For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn


Novartis Oncology is a leading innovator in cancer research and care, providing patients with the access to the essential therapy. With over 10,000 associates in more than 85 countries, we are one of the largest global developers and providers of practice-changing innovative medicines. Novartis Oncology was allocated as a business division in 2016 upon the termination of merger with the GSK oncological portfolio. Today the unparalleled portfolio of Novartis Oncology includes more than 20 drugs on the market and more than 30 new molecular entities in development targeting key molecular pathways in cancer biology. 10-years strategy of the division is focused on obtaining leadership in five key therapeutic areas – breast, lung, liver, melanoma and hematocytology, and strives to fulfill key mission of Novartis Oncology business - to transform the way patients live with cancer and related diseases.


Pfizer is one of the world's leading biopharmaceutical companies. It was founded over 160 years ago with headquarters located in New York (USA). Every year Pfizer’s medications help more than 150 million people to fight their diseases and lead a healthy lifestyle. The diversified portfolio includes both innovative and long-established products: prescription drugs and vaccines, as well as a number of well-known over-the-counter medications for maintaining health.

Roche Moscow Ltd.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit

General partner

Merck LLC

Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.


Servier is an international pharmaceutical company governed by a non-profit foundation. With a strong international presence in 149 countries, Servier employs 22 000 people worldwide. Corporate growth is driven by Servier’s constant search for innovation in five therapeutic areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes.

Servier has been operating in Russia for almost 30 years, remaining one of the leading pharmaceutical companies. In 2007, a full-cycle pharmaceutical plant Servier RUS was launched in Moscow.

More information:


«Sotex» PharmFirm» CJSC

«Sotex» is one of the biggest domestic pharmacological producers. Oncology including supportive therapy (erythropoietin alpha, Eralphon) is among the most important corporate therapeutic fields


BioVitrum produces about 300 products for laboratory diagnostics and supplies products from leading manufacturers of diagnostic equipment and consumables.

Our team successfully develops and implements innovative medical information systems and solutions for telemedicine, combining all aspects of oncological diagnostics within a single infrastructure and provides different medical professionals with the opportunity to work together wherever they are

Boehringer Ingelheim

Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards humankind and the environment.

More information about Boehringer Ingelheim can be found on or in our annual report


Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s vision is to become a leading global biotech company focused on innovation and specialty care. Ipsen’s commitment to oncology is exemplified through its growing portfolio. Ipsen sells 9 drugs in primary care and specialty including aesthetics.
109147, Taganskaya str., 17-23, Moscow, Russia
Tel.: +7 495 258 54 00
Fax: +7 495 258 54 01

JSC «R-Pharm»

R-Pharm Group is a leading Russian healthcare company. It improves accessibility of modern and efficient methods related to medical diagnostics, preventative care and disease treatment.  R-Pharm operates in Russia, CIS states and other countries


KARL STORZ company presents the latest visualization technologies on the video system IMAGE 1S - ICG technologies, near infrared detection for evaluation of lymphatic drainage and location of signaling lymph nodes, perfusion in tissues and complexes of high-resolution 3D

LLC Philips

Philips is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2017 sales of EUR 17.8 billion and employs approximately 74,000 employees with sales and services in more than 100 countries. News about Philips can be found at


As a global leader in medical technology, services and solutions, Medtronic improves the health and lives of millions of people each year. We believe our deep clinical, therapeutic and economic expertise can help address the complex challenges — such as rising costs, aging populations and the burden of chronic disease — faced by families and healthcare systems today. But no one can do it alone. That’s why we’re committed to partnering in new ways and developing powerful solutions that deliver better patient outcomes.

Founded in 1949 as a medical repair company, we’re now among the world’s largest medical technology, services and solutions companies, employing more than 85,000 people worldwide, serving physicians, hospitals and patients in nearly 155+ countries.

Join us in our commitment to take healthcare Further, Together. Learn more at

Nutricia Specialized Nutrition

Nutricia Specialized Nutrition, a division of Danone, is an international company and one of the leaders in the Russian market of baby and specialized nutrition. The Company works in the several key areas: pediatrics, allergology, intensive care, oncology, dietology, nutritiology and metabolic disorders of metabolism.


The Pharmasyntez Group is a Russian pharmaceutical company, which is engaged in development and production of up-to-date, high quality and affordable medicines for the treatment of socially significant diseases such as tuberculosis, HIV/AIDS, oncology, diabetes mellitus, hepatitis and blood diseases

Pierre Fabre

Pierre Fabre, the private pharmaceutical company in France, is well known all over the world not only for its medications, but for medicinal cosmetics. The medicines include those for oncological diseases – Navelbine and Javlor, for infantile hemangioma – Hemangiol, for treatment of musculoskeletal system disorders - Structum and Osteogenon, for prevention of iron deficiency conditions – Tardyferon, for benign prostatic hyperplasia Permixon, as well as dental products for oral care.


Sanofi is a leading global biopharmaceutical company. The company is represented in 100 countries; its headcount is about 110,000 people globally. Sanofi acts to protect health, enhance life and respond to the hopes and potential healthcare needs of 7 billion people around the world.

The company's oncology portfolio is represented in such nosologies as breast and pancreatic cancer - Abraxane; prostate cancer - Jevtana; thyroid cancer - Thyrogen, Caprelsa; colorectal cancer - Zaltrap.